Details for Patent: 9,901,640

Which drugs does patent 9,901,640 protect, and when does it expire?

Patent 9,901,640 protects RYTARY and is included in one NDA.

This patent has twenty-five patent family members in twelve countries.

Summary for Patent: 9,901,640

Patent landscape, scope, and claims:

Title:	Controlled release formulations of levodopa and uses thereof
Abstract:	A modified release levodopa dosage form.
Inventor(s):	Hsu; Ann (Los Altos Hills, CA), Kou; Jim (San Jose, CA), Alani; Laman (Fort Worth, TX)
Assignee:	Impax Laboratories, Inc. (Hayward, CA)
Application Number:	15/382,851
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,901,640
Patent Claim Types: see list of patent claims	Use; Composition; Compound; Dosage form;

Drugs Protected by US Patent 9,901,640

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-001	Jan 7, 2015		RX	Yes	No	9,901,640		Y			TREATMENT OF PARKINSON'S DISEASE
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-002	Jan 7, 2015		RX	Yes	No	9,901,640		Y			TREATMENT OF PARKINSON'S DISEASE
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-003	Jan 7, 2015		RX	Yes	No	9,901,640		Y			TREATMENT OF PARKINSON'S DISEASE

International Family Members for US Patent 9,901,640

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2008343787
Canada	2711014
China	101910113